|
|
Post by mnholdem on Oct 30, 2015 21:43:45 GMT -5
The reporter misspelled his name, but reported Matt Pfeffer's comments. He hopes that MannKind's products will be in Israeli hospitals soon:
Matthew Pepper, Vice president and CFO of MannKind, who took the stage and rang the TASE opening bell added, "I am proud and excited to be in Israel to list Mannkind for trade on the TASE. This is the first step of the company in Israel which reflects our intention to maintain a long term relationship with the Israeli capital market and the local biomedical industry. MannKind managed to promote a product throughout all stages of development to marketing approval and to market. Our ability to deliver insulin through an inhaler involves a revolutionary technology and I hope that our collaboration with Sanofi will help the inhaler also enter the Israeli hospitals soon. We are going to continue to develop the unique technology also for additional medical indications."
www.mondovisione.com/media-and-resources/news/tel-aviv-stock-exchange-opening-bell-ceremony-with-mannkind-corporation/
|
|
|
|
Post by jay1ajay1a on Oct 30, 2015 22:04:05 GMT -5
Great find.
|
|
|
|
Post by vestful on Oct 31, 2015 1:14:43 GMT -5
Speaks volumes...great post!
|
|
|
|
Post by EveningOfTheDay on Oct 31, 2015 3:31:53 GMT -5
I could be wrong, but this sounds more like something one said because one is invited to ring the opening bell, than something based on what one knows is coming. Of course I could be wrong. Will see.
|
|
|
|
Post by EveningOfTheDay on Oct 31, 2015 3:35:21 GMT -5
Actually I stand corrected. I am borrowing this from another thread, but,
"Roni Birinboym, CEO of Sanofi in Israel: "Inhaled insulin AFREZZA save diabetics from having to do injections and greatly facilitate their lives. This is a real revolution in the world of pharmacology. Our company will do everything necessary to deliver as soon as possible this insulin in Israel."
Looking forward to it.
|
|
|
|
Post by mnholdem on Oct 31, 2015 6:33:49 GMT -5
You're right though, EOTD. When you think about it, "as soon as possible" can mean 1-2 months or 1-2 years...  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 31, 2015 6:44:55 GMT -5
You're right though, EOTD. When you think about it, "as soon as possible" can mean 1-2 months or 1-2 years... ;) True MN but as a small country, far less hurdles and bureaucracy to deal with so hopefully sooner rather than later. With socialized medicine, perhaps they can run a real world study with a few hundred patients and show the before and after over a 3-4 month time period. Then publish in a peer review article and end any doubt about how much better Afrezza performs in the real world vs the RAAs. In an interconnected world, a global online campaign that originates out of Israel can reach the masses, not run afoul of regulatory issues and put a stake in the heart of the naysayers. Israel is one scrappy little country, too funny if Afrezza's big break comes from there. |
|
|
|
Post by falconquest on Oct 31, 2015 8:15:15 GMT -5
The reporter misspelled his name, but reported Matt Pfeffer's comments. He hopes that MannKind's products will be in Israeli hospitals soon:
Matthew Pepper, Vice president and CFO of MannKind, who took the stage and rang the TASE opening bell added, "I am proud and excited to be in Israel to list Mannkind for trade on the TASE. This is the first step of the company in Israel which reflects our intention to maintain a long term relationship with the Israeli capital market and the local biomedical industry. MannKind managed to promote a product throughout all stages of development to marketing approval and to market. Our ability to deliver insulin through an inhaler involves a revolutionary technology and I hope that our collaboration with Sanofi will help the inhaler also enter the Israeli hospitals soon. We are going to continue to develop the unique technology also for additional medical indications."
www.mondovisione.com/media-and-resources/news/tel-aviv-stock-exchange-opening-bell-ceremony-with-mannkind-corporation/
I would like to see Matt and Hakan banish the word "hope" from their vocabulary. It would sound so much better if they said, "we believe". This is good news however. |
|
|
|
Post by mnholdem on Oct 31, 2015 8:30:26 GMT -5
We've heard them say EU and Japan - Hakan even mentioned China during one conference - but, if I'm not mistaken, Matt's remark is the first time Israel has been mentioned by anyone from management. Of course, when you consider that Sanofi sells pharmaceuticals in 120 countries, you realize that Israel sales would be the equivalent of a single berry from the entire pie.
|
|
|
|
Post by kball on Oct 31, 2015 8:40:53 GMT -5
Ok I'll play Devil's Advocate.
That might have been a subtle dig at Sanofi.
But why would Matt use 'Hospitals' rather than approval in Israel in general?
For quick mega correction doses when patients arrive with sky high BS?
As usual, more questions than answers.
Can we get some doctors here to chime in as to why Matt thought hospitals was of greater significance to mention
|
|
|
|
Post by liane on Oct 31, 2015 8:50:31 GMT -5
I noticed that too, but not knowing health care is delivered in Israel, I don't know the significance. It could be that all physicians are employed by hospitals and thus the hospitals dictate policy - but I truly don't know.
|
|
|
|
Post by peppy on Oct 31, 2015 8:57:52 GMT -5
Ok I'll play Devil's Advocate. That might have been a subtle dig at Sanofi. But why would Matt use 'Hospitals' rather than approval in Israel in general?For quick mega correction doses when patients arrive with sky high BS? As usual, more questions than answers. Can we get some doctors here to chime in as to why Matt thought hospitals was of greater significance to mention Sorry to repeat myself. In answer to the question; Many corticsteriods given in hospitals to reduce what we call inflammation. One of the side effects of corticosteroids is their effect on blood sugar.
Glucocorticoids stimulate the process of hepatic gluconeogenesis, resulting in elevated plasma glucose, which, in turn, promotes the deposition of liver glycogen.34 Increased hepatic gluconeogenesis/glycogenesis is due to direct effects of glucocorticoids on the hepatic expression of genes that code for enzymes required for glucose and glycogen biosynthesis. Prolonged exposure to glucocorticoids leads to a diabetic-like state due to the increase in plasma glucose, www.ncbi.nlm.nih.gov/books/NBK13780/ Glucocorticoids stimulate the conversion of protein to carbohydrate through gluconeogenesis and promote the storage of carbohydrate as glycogen ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ I am the only one to voice this, hospitals need afrezza. spirometry, no problem. List of corticosteroids; www.livestrong.com/article/27014-list-corticosteroid-medications/ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
|
|
|
Post by kball on Oct 31, 2015 9:29:31 GMT -5
^ So for corrections, rather than treating? I get that. Saw that happen to my mom when they gave her those.
But why was THAT highlighted? As we are not even seeing that here yet in america to the best of my knowledge
|
|
|
|
Post by dpca10 on Nov 1, 2015 21:18:14 GMT -5
Afrezza isn't approved or indicated for treatment of Ketoacidosis or non ketotic coma as far as I know. Administration of very large doses of insulin in hyperglycemic crisis leads to dangerous shifts in potassium. In these cases a single dose might be helpful but an insulin infusion along with fluid rehydration and electrolyte monitoring is the standard of care. Don't read too much of "into hospitals." I think the word approval has become stigmatized in mnkd's corporate culture, looking for other ways to say the same thing.
|
|
|
|
Post by rrtzmd on Nov 1, 2015 22:43:22 GMT -5
The reporter misspelled his name, but reported Matt Pfeffer's comments. He hopes that MannKind's products will be in Israeli hospitals soon:
Matthew Pepper, Vice president and CFO of MannKind, who took the stage and rang the TASE opening bell added, "I am proud and excited to be in Israel to list Mannkind for trade on the TASE. This is the first step of the company in Israel which reflects our intention to maintain a long term relationship with the Israeli capital market and the local biomedical industry. MannKind managed to promote a product throughout all stages of development to marketing approval and to market. Our ability to deliver insulin through an inhaler involves a revolutionary technology and I hope that our collaboration with Sanofi will help the inhaler also enter the Israeli hospitals soon. We are going to continue to develop the unique technology also for additional medical indications."
www.mondovisione.com/media-and-resources/news/tel-aviv-stock-exchange-opening-bell-ceremony-with-mannkind-corporation/
I would like to see Matt and Hakan banish the word "hope" from their vocabulary. It would sound so much better if they said, "we believe". This is good news however. For all intents and purposes, it might be best simply to ban Matt and Hakan from saying anything, period. |
|
